The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Journal of the National Comprehensive Cancer Network : JNCCN - United States
doi 10.6004/jnccn.2017.0049
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2017
Authors
Publisher
Harborside Press, LLC